
Stevenage Bioscience Catalyst hires first entrepreneur-in-residence
pharmafile | December 13, 2012 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | Stevenage Bioscience Catalyst
Early-stage biotech firm Stevenage Bioscience Catalyst (SBC) has appointed Dr Barbara Domayne-Hayman as its first entrepreneur-in-residence.
Domayne-Hayman will work with SBC and its tenants on strategy, as well as new business creation, with an initial focus on cell therapy and neuroscience. She is also a member of the recently established SBC Experts Panel.
Domayne-Hayman is a company builder and dealmaker, who has transitioned from working in large organisations to an entrepreneurial environment. During her time as chief executive of Stabilitech and commercial director of Arrow Therapeutics, she was responsible for multiple agreements, developing teams and bringing in funding.
Prior to Arrow, Domayne-Hayman held business positions at Celltech and Zeneca, and consulted for Ernst & Young Strategy Group.
“We are delighted to have appointed Barbara, with her ideal skill set, as our first entrepreneur-in-residence,” said Dr Martino Picardo, chief executive of Stevenage Bioscience Catalyst.
Related Content

Sanofi reinforces collaboration with Stevenage Bioscience Catalyst with partnering office
Sanofi has reinforced its collaboration with Stevenage Bioscience Catalyst with the opening of a new …






